Skip to main content
. 2013 Oct 20;6:95–111. doi: 10.4137/MRI.S12561

Table 3.

Properties and approval status of extracellular gadolinium-based contrast agents.a

CHEMICAL NAME TRADE NAME MANUFACTURER CHARGE AND CHEMICAL STRUCTURE CONCENTRATION (mol/L) KINETIC STABILITYb RELAXIVITY (3 T IN PLASMA, 37°C) [L/mmol−1s−1] T1 SHORTENING TIME (MS) IN BLOOD FOR 1 mL/L AGENT VISCOSITY [mPa*s] OSMOLALITY [mOsm/kg H2O] EXCRETION RECOMMENDED DOSES FOR IMAGING (mmol/kg) APPROVED DOSES FOR CHILDREN (mmol/kg)
Gadodiamide Omniscan GE Healthcare Nonionic linear 0.5 35 s 4.0 880.85 1.4 790 Renal Body 0.1
CNS 0.1
Kidney 0.05
Intrathoracic, intra-abdominal, pelvic 0.1
From 2 years: 0.1
Gadopentetate dimeglumine Magnevist Bayer Ionic linear 0.5 10 min 3.7 864.80 2.9 1960 Renal CNS 0.1
Extracranial/ extraspinal 0.1
Body 0.1
From 2 years: 0.1
Gadobenate dimeglumine MultiHance Bracco Ionic linear 0.5 N/A 5.5 960.96 5.3 1970 Renal, 4–5% hepatobiliary CNS 0.1
MRA 0.1
From 2 years: 0.1
Gadoversetamide OptiMARK Tyco Nonionic linear 0.5 N/A 4.5 N/A 2.0 1110 Renal CNS 0.1
Liver 0.1
Not approved <18 years
Gadoterate meglumine Dotarem Guerbet Ionic cyclic 0.5 >1 month 3.5 859.0 2.0 1350 Renal CNS 0.1
Extracranial/ extraspinal 0.1
Body 0.1
Infants and children: 0.1
Gadoteridol ProHance Bracco Nonionic cyclic 0.5 3 h 3.7 870.33 1.3 630 Renal CNS 0.1
Extracranial/ extraspinal 0.1
From 2 years: 0.1
Gadobutrol Gadovist, Gadavist Bayer Nonionic cyclic 1.0 24 h 5.0 1036.96 4.96 1390 Renal CNS 0.1
Liver 0.1
Kidney 0.1
MRA 0.1
Whole body (EU) 0.1
From 2 years: 0.1
Gadoxetic acid Primovist Bayer Ionic linear 0.5 N/A 6.2 N/A 1.19 668 50% renal, 50% hepatobiliary Liver 0.025 Not approved <18 years
a

Please consult your local prescribing information for the latest information on approved indications and dosing.

b

Kinetic stability: dissociation half-life at pH 1.0.